Dal-Outcomes II

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Stadium: klaar
Middel: dalcetrapib
Populatie: ASCVD
Fase: III
First Patient In: 1 september 2011
Last Patient In: -
Last Patient Last Visit: -

Studiedirecteur

dr. E. Ronner

Cardioloog